GNH USA

Europe — EMA

Novantron (Mitoxantrone)

GNH USA supplies Novantron (Mitoxantrone), a anthracenedione antineoplastic agent for acute myeloid leukemia, prostate cancer and other malignancies.

Mitoxantrone

Request sourcing

1
Pack/s

What is Mitoxantrone?

Mitoxantrone, the active ingredient in Novantron, is an anthracenedione presented as an intravenous formulation for infusion use. It is employed in the treatment of certain hematologic malignancies and solid tumors in adult patients.

GNH USA supplies Novantron as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to European Union quality standards and provides regulatory documentation for importers. Novantron is manufactured under GMP conditions and distributed through a temperature‑controlled logistics network to ensure product integrity.

What is Mitoxantrone used for?

Novantron (mitoxantrone) is used in the management of malignant diseases that involve rapidly dividing cells.

- Acute myeloid leukemia: improves remission rates and prolongs survival in adult patients. - Prostate cancer: provides disease control in hormone‑refractory cases. - Breast cancer: used in metastatic disease to achieve tumor reduction. - Non‑Hodgkin lymphoma: contributes to response in relapsed or refractory disease.

What are the side effects of Mitoxantrone?

Novantron may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Fatigue: persistent tiredness affecting daily activities. - Alopecia: reversible hair loss during treatment. - Myelosuppression: reduced white blood cells, red cells, and platelets.

Serious or Rare Side Effects: - Cardiotoxicity: decreased left‑ventricular ejection fraction, potentially irreversible. - Secondary leukemia: emergence of a new hematologic malignancy. - Severe infection: opportunistic infections due to profound neutropenia. - Pulmonary toxicity: interstitial pneumonitis or fibrosis.

What precautions apply to Mitoxantrone?

When using Novantron, clinicians should observe several safety measures to minimize risks.

- Cardiac monitoring: baseline and periodic ejection‑fraction assessments are recommended. - Hematologic surveillance: regular complete blood counts to detect myelosuppression. - Liver function: periodic liver‑enzyme testing for hepatic toxicity. - Contraindication in severe cardiac disease: avoid in patients with pre‑existing heart failure. - Pregnancy and lactation: avoid unless benefits outweigh potential fetal or neonatal risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

What does Mitoxantrone interact with?

Novantron can interact with several agents, requiring careful management.

Major Interactions (Avoid): - Concurrent anthracyclines: additive cardiotoxicity may be life‑threatening. - Live vaccines: immunosuppression can lead to uncontrolled infection. - High‑dose radiotherapy: increased risk of tissue damage.

Moderate Interactions (Monitor Closely): - Anticoagulants: heightened bleeding risk due to thrombocytopenia. - CYP3A4 inhibitors: may increase mitoxantrone plasma concentrations. - Granulocyte‑colony stimulating factors: may mask severity of myelosuppression.

Frequently asked questions

What is Novantron used for?+
Novantron is the brand name for the chemotherapy agent mitoxantrone. It is indicated for the treatment of acute myeloid leukemia, hormone‑refractory prostate cancer, metastatic breast cancer, and relapsed or refractory non‑Hodgkin lymphoma in adult patients.
How does mitoxantrone work?+
Mitoxantrone intercalates into DNA and blocks the activity of topoisomerase II, an enzyme required for DNA replication. This inhibition creates double‑strand breaks, disrupts transcription, and triggers apoptosis of rapidly dividing cancer cells.
What is the usual dose of Novantron?+
The dosing regimen for Novantron is individualized by the treating oncologist based on the specific cancer type, disease stage, patient weight, renal function, and prior therapies. Only a qualified prescriber can determine the appropriate dose and schedule.
Is Novantron safe in pregnancy or breastfeeding?+
Safety data for mitoxantrone in pregnancy and lactation are limited. The drug is generally avoided during pregnancy and breastfeeding because of potential fetal toxicity and excretion in breast milk. Use only if the potential benefit justifies the risk.
How do I order Novantron from GNH USA?+
To request Novantron, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and the necessary import documentation.
How does Novantron compare with the main alternative drug or class?+
Novantron belongs to the anthracenedione class, which is chemically related to anthracyclines such as doxorubicin. Compared with anthracyclines, mitoxantrone has a lower incidence of acute cardiotoxicity at equivalent doses but still requires cardiac monitoring. Both classes share myelosuppression as a common toxicity.
How should Novantron be stored and handled?+
Novantron must be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. The product should be kept in its original packaging until preparation, and handling should follow aseptic techniques to maintain sterility.
How is Novantron administered?+
Novantron is supplied as an injectable solution for intravenous infusion. It is administered by a qualified healthcare professional, typically over a period of 30‑60 minutes, depending on the prescribed dose and patient tolerance.
What are the most serious risks to watch for while on Novantron?+
The most serious adverse events include cardiotoxicity (reduced left‑ventricular function), secondary acute leukemia, severe myelosuppression leading to infection or bleeding, and pulmonary toxicity. Patients should be monitored regularly for cardiac function, blood counts and respiratory symptoms.
Who should not use Novantron?+
Novantron is contraindicated in patients with pre‑existing severe cardiac disease, uncontrolled infections, or known hypersensitivity to mitoxantrone or any formulation component. It should also be avoided in pregnant women unless the therapeutic benefit outweighs the potential fetal risk.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Mitoxantrone
Route
Intravenous Use
Manufacturer
Viatris Healthcare Gmbh
Origin
EU

Related products

Mitoxan

Mitoxan

Mitoxantrone

Medicamerc S.A
EU
Mitoxantron "ebewe"

Mitoxantron "ebewe"

Mitoxantrone

Ebewe Pharma
EU
Mitoxantron Accord

Mitoxantron Accord

Mitoxantrone

Accord Healthcare B.V.
EU
Mitoxantron Ebewe

Mitoxantron Ebewe

Mitoxantrone

Ebewe Pharma
EU